Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lorcaserin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C known ✓ | P28335 | 20/20 | 1.00 |
| ▸ | HTR2A | P28223 | 20/20 | 1.00 |
| ▸ | HTR2B | P41595 | 18/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lorcaserin SCHEMBL5946555 | 1.00 | HTR2A (1.00) | HTR2AHTR2CHTR2BADRB1HTR1A | |
| Lorcaserin SCHEMBL1094953 | 1.00 | HTR2A (1.00) | HTR2AHTR2CHTR2BADRB1HTR1A | |
| Lorcaserin SCHEMBL29349440 | 1.00 | HTR2A (1.00) | HTR2AHTR2CHTR2BADRB1HTR1A | |
| Lorcaserin SCHEMBL170848 | 1.00 | HTR2A (1.00) | HTR2AHTR2CHTR2BADRB1HTR1A | |
| Lorcaserin SCHEMBL1954700 | 0.98 | HTR2A (0.97) | HTR2AHTR2CHTR2BADRB1HTR1A | |
| Lorcaserin SCHEMBL171009 | 0.98 | HTR2A (0.97) | HTR2AHTR2CHTR2BADRB1HTR1A | |
| Lorcaserin SCHEMBL174046 | 0.98 | HTR2A (0.97) | HTR2AHTR2CHTR2BADRB1HTR1A | |
| Lorcaserin SCHEMBL174044 | 0.98 | HTR2A (0.97) | HTR2AHTR2CHTR2BADRB1HTR1A | |
| Lorcaserin SCHEMBL16672993 | 0.98 | HTR2A (0.97) | HTR2AHTR2CHTR2BADRB1HTR1A | |
| Lorcaserin SCHEMBL173899 | 0.98 | HTR2A (0.97) | HTR2AHTR2CHTR2BADRB1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 877 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220252537-A1 | NEW POLYMER MATRIX ELECTRODES | TECNOSENS S.R.L. (IT) | 2022-08-11 | — | — | US | claimed |
| US-20220193082-A1 | COMBINATION TREATMENT OF SPECIFIC FORMS OF EPILEPSY | ZOGENIX INTERNATIONAL LIMITED (GB) | 2022-06-23 | — | — | US | claimed |
| EP-3994456-A1 | NEW POLYMER MATRIX ELECTRODES | Tecnosens Srl (IT) | 2022-05-11 | — | — | EP | claimed |
| CN-111499575-B | Method for preparing lorcaserin | 河北师范大学 | 2022-03-25 | — | — | CN | claimed |
| US-20210052600-A1 | THERAPEUTIC AGENTS FOR STRESS URINARY INCONTINENCE AND INCOTINENCE OF FECES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-02-25 | — | — | US | claimed |
| EP-3733204-A1 | THERAPEUTIC AGENT FOR STRESS URINARY INCONTINENCE AND FECAL INCONTINENCE | Takeda Pharmaceutical Company Limited (JP) | 2020-11-04 | — | — | EP | claimed |
| CN-111499575-A | Method for preparing lorcaserin | 河北师范大学 | 2020-08-07 | — | — | CN | claimed |
| US-10463676-B2 | Modified-release dosage forms of 5-HT2C agonists useful for weight management | ARENA PHARMACEUTICALS, INC. (US) | 2019-11-05 | — | — | US | claimed |
| US-20190275055-A1 | Modified-Release Dosage Forms of 5-Ht2c Agonists Useful for Weight Management | ARENA PHARMACEUTICALS, INC. | 2019-09-12 | — | — | US | claimed |
| EP-3485878-A1 | MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT | Arena Pharmaceuticals, Inc. (US) | 2019-05-22 | — | — | EP | claimed |
| EP-1838677-B1 | CRYSTALLINE FORMS OF (R)-8-CHLORO-1-METHYL- 2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE HYDROCHLORIDE | ARENA PHARM INC (US) | 2009-09-09 | — | — | EP | claimed |
| EP-1833473-B1 | 5HT2C RECEPTOR MODULATOR COMPOSITIONS AND METHODS OF USE | ARENA PHARM INC (US) | 2009-09-09 | — | — | EP | claimed |
| US-20090197868-A1 | 5ht2c receptor modulator compositions and methods of use | ARENA PHARMACEUTICALS, INC. | 2009-08-06 | — | — | US | claimed |
| US-20090143576-A1 | Processes for the Preparation of 8-Chloro-1-Methyl-2,3,4,5-Tetrahydro-1H-3-Benzazepine and Intermediates Related Thereto | ARENA PHARMACEUTICALS, INC. | 2009-06-04 | — | — | US | claimed |
| US-7514422-B2 | 5HT2c receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2009-04-07 | — | — | US | claimed |
| EP-2001852-A2 | PROCESSES FOR THE PREPARATION OF 8-CHLORO-1-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE AND INTERMEDIATES RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2008-12-17 | — | — | EP | claimed |
| WO-2007120517-A2 | PROCESSES FOR THE PREPARATION OF 8-CHLORO-1-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE AND INTERMEDIATES RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-10-25 | — | — | WO | claimed |
| EP-1833473-A2 | 5HT2C RECEPTOR MODULATOR COMPOSITIONS AND METHODS OF USE | Arena Pharmaceuticals, Inc. (US) | 2007-09-19 | — | — | EP | claimed |
| WO-2006071740-A2 | 5HT2C RECEPTOR MODULATOR COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. (US) | 2006-07-06 | — | — | WO | claimed |
| US-6953787-B2 | 5HT2C receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2005-10-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10463676-B2 | Modified-release dosage forms of 5-HT2C agonists useful for weight management | HTR2C, HTR2A, HTR3C | HTR2C 1/4885HTR2A 2/4885HTR2B 8/4885 |
| US-20220193082-A1 | COMBINATION TREATMENT OF SPECIFIC FORMS OF EPILEPSY | HTR2B, HTR3B, HTR5A | HTR2C 8/4885HTR2A 7/4885HTR2B 1/4885 |
| US-20090143576-A1 | Processes for the Preparation of 8-Chloro-1-Methyl-2,3,4,5-Tetrahydro-1H-3-Benzazepine and Intermediates Related Thereto | HTR2C, HTR3C, HTR1A | HTR2C 1/4885HTR2A 12/4885HTR2B 17/4885 |
| US-20090197868-A1 | 5ht2c receptor modulator compositions and methods of use | HTR2C, HTR5A, HTR2A | HTR2C 1/4885HTR2A 3/4885HTR2B 11/4885 |
| US-20190275055-A1 | Modified-Release Dosage Forms of 5-Ht2c Agonists Useful for Weight Management | HTR2C, HTR2A, HTR3C | HTR2C 1/4885HTR2A 2/4885HTR2B 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.